No toxic effects have been reported at any dose tested in animal research. However, human safety data is extremely limited. No large clinical trials have evaluated long-term safety. Unknown risks remain, particularly regarding its pro-angiogenic mechanism. Clinical supervision is strongly recommended.

Animal research consistently demonstrates accelerated healing across multiple tissue types. These findings are remarkably reproducible across different research groups and injury models. However, results in animal models do not guarantee human efficacy, and no controlled human trials have confirmed these effects.

How long does BPC-157 take to show effects?

Measurable improvements in tissue repair have been observed within 3 to 14 days in animal studies, depending on the injury model and dosing protocol. Human timelines are not established through controlled research.

Is BPC-157 FDA approved?

No. BPC-157 has not been approved by the FDA or any major regulatory body for therapeutic use. It is classified as a research peptide. It is listed as a prohibited substance by WADA (World Anti-Doping Agency).

What tissue repair evidence exists for this compound?

Tissue repair replicated across 5+ distinct injury types, including tendon, ligament, muscle, GI mucosa, and liver, with consistent acceleration in every model tested. This breadth of replication across injury types is rare for any research peptide and is the primary reason BPC-157 draws continued attention

What mechanism of action has been identified?

Multi-pathway mechanism spans FAK-paxillin, NO system, and VEGF/EGF/FGF upregulation, unusually broad for a 15-amino-acid peptide. The mechanistic diversity may explain why effects appear in such different tissue types, but also makes the compound harder to study in targeted human trials

What gut protective effects have been observed?

GI cytoprotection demonstrated against NSAIDs, alcohol, and stress-induced damage, the most internally consistent outcome category. If any BPC-157 claim advances to human trials first, GI protection is the most likely candidate based on preclinical strength

What are the research concentration concerns?

Majority of published research originates from a single group (Sikiric et al., University of Zagreb), a significant replication concern. Independent labs have reproduced some findings, but the concentration of output from one team limits confidence in the overall body of evidence

Have any randomized controlled human trials been completed?

Zero completed randomized controlled human trials as of early 2026, despite 20+ years of animal research. This is the single largest barrier to a higher evidence rating and the reason BPC-157 cannot be described as clinically validated

reviewed april 2026|next review october 2026|88 physicians psi has verified|212 published studies

BPC-157

BPC-157 is a synthetic peptide derived from a protein found in human stomach fluid, studied primarily for tissue repair and gut protection. It is not an approved medicine.

Evidence landscape: 212 published studies

212 published items: 3 human studies and 157 animal studies. For a research peptide without a commercial development program, this is one of the largest animal study evidence bases in the peptide space.

4 Human
156 Animal
40 Reviews
12 Other research

Not a prescription medicine in the U.S. A doctor cannot currently write a prescription for it, though the legal rules may be changing.

Most research is in animals, not humans. Fewer than 30 people total have been studied in small pilot trials, which are early-stage studies with a small number of participants. No large human study has been completed.

Most of the research comes from a single scientific group at the University of Zagreb. That is unusual and it is a real limitation of the evidence.

PSI Assessment

More than 200 published studies have investigated BPC-157 for tissue repair, gut healing, and inflammation, and the results in animal models are consistently positive across every tissue type tested. That is one of the largest and most consistent animal research bases of any peptide not approved as a medicine. But the distance between animal evidence and human confirmation is wider here than almost anywhere else in the peptide space: three pilot studies totaling fewer than 30 participants, with no control groups, in more than 20 years of research. More than half of all published work comes from a single research group at the University of Zagreb.

The animal data is unusually strong. The human data gap is also unusually large. Both are true simultaneously.

The mechanism works through multiple pathways simultaneously, which is unusual for a peptide this small: blood vessel formation (angiogenesis), growth factor upregulation (VEGF, EGF, FGF), and nitric oxide system modulation. That multi-pathway profile is the mechanistic reason effects appear across such diverse tissue types rather than being limited to one organ. It also explains why no single focused human trial has been designed: the breadth of the preclinical signal across animal studies makes it harder to choose one indication to test first.

What the evidence supports

Animal studies consistently show accelerated tissue repair across tendons, ligaments, muscles, gut lining, and liver. Independent replication outside the Zagreb group exists for several tissue types. The preclinical consistency is stronger than most research peptides achieve.

What is not yet established

Controlled human trials. Three pilot studies totaling fewer than 30 participants exist, with no control groups. Whether any of the animal results translate to humans at meaningful doses. Whether the Zagreb group concentration weakens the overall evidence base.

Research Evidence

The findings below add the replication, concentration, and translational context that the headline numbers do not carry.

Evidence by condition

Evidence dimensions across BPC-157's investigated conditions. Gut protection has the broadest evidence signature including limited human data. Injury healing has strong animal replication. Neuroprotection and muscle/fat claims have the thinnest support.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Injury Healing
Gastrointestinal Protection
Cognitive / Neuroprotective
Muscle Growth
Fat Loss

Animal studies show accelerated healing across tendons, ligaments, muscles, gut lining, and liver. Independent laboratories outside the Zagreb group have reproduced several of these findings.

Consistent results across this many tissue types is rare for any research compound. It is the primary reason BPC-157 continues to attract scientific interest despite the limited human data.

More than half of all published BPC-157 research comes from a single group at the University of Zagreb, led by Professor Predrag Sikiric.

In science, confidence in a finding grows when different teams in different laboratories get the same result. Independent replication exists but is thinner than the total study count suggests.

Gut protection is the most internally consistent outcome category. Animal studies show reduced ulcer formation and faster mucosal healing against damage from NSAIDs, alcohol, and stress.

If any BPC-157 indication advances to a large human trial first, gut protection has the strongest and most consistent preclinical signal across animal studies to justify the investment.

4 Human|156 Animal|40 Reviews

View all 212 indexed studies

How BPC-157 Works

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein fragment identified in human gastric juice. It is studied primarily for tissue repair and gastrointestinal protection.

BPC-157 appears to tell your body to send more blood and repair signals to injured areas. Think of it as potentially turning up the volume on your body's natural healing process, but this has only been shown in animal studies so far.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

BPC-157 appears to promote blood vessel growth (a process called angiogenesis) and signal tissue-repair cells to migrate to injured sites. It increases three growth factors (VEGF, EGF, and FGF), which are molecules that tell cells to multiply and rebuild damaged tissue. It also interacts with the nitric oxide system, a chemical signaling pathway your body uses to control blood flow and inflammation.

What is BPC-157 being studied for?

Researchers are studying BPC-157 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for BPC-157 overall. This means a compound can have human studies for one condition but only animal data for another.

Injury Healing

·Animal Studies

Research in animal models suggests BPC-157 accelerates healing of tendons, ligaments, and muscles. Tendon-to-bone healing, Achilles tendon repair, and muscle crush injuries have all shown faster recovery in rodent studies.

Limitations: All healing data comes from rodent models. No controlled human injury healing trials exist. Dosing, timing, and route of administration in humans are not established.

Gastrointestinal Protection

·Human Trials

Animal studies and a small human pilot suggest BPC-157 may help protect the stomach and intestinal lining against damage from NSAIDs (non-steroidal anti-inflammatory drugs like ibuprofen), alcohol, and stress. Effects observed include reduced ulcer formation and faster mucosal healing.

Limitations: Human gastrointestinal data is limited to anecdotal reports and case series. No randomized trials in inflammatory bowel disease, irritable bowel syndrome, or ulcer populations have been published.

Cognitive / Neuroprotective

·Animal Studies

Animal studies show BPC-157 has neuroprotective properties, including protection against damage to dopamine-producing brain cells. The biological mechanisms behind these effects are still being investigated.

Limitations: Neuroprotection data is limited to a small number of animal studies. Mechanisms are not fully characterized. No human neurological studies exist.

Muscle Growth

·Preclinical

Not primarily studied for muscle growth. Any muscle-related benefits appear secondary to injury healing properties.

Limitations: No studies specifically investigate BPC-157 for muscle hypertrophy or performance enhancement.

Fat Loss

·Preclinical

No meaningful research investigating BPC-157 for fat loss or metabolic effects. Not a metabolic peptide.

Safety and Regulatory Status

FDA Status: Not approved in the United States for any indication. A doctor cannot currently write a prescription for it.

Legal access: A doctor cannot currently have BPC-157 prepared through a specialty pharmacy, where a licensed pharmacist ordinarily prepares a medicine from ingredients for an individual patient. That access route is expected to be restored, pending the final FDA update.

International status: No known non-US regulatory approval. The World Anti-Doping Agency classifies BPC-157 as a prohibited substance in sport, meaning competitive athletes cannot use it.

No harmful effects have been reported in animal studies at any dose tested. But human safety data is extremely limited, because so few people have been studied. BPC-157 is on the World Anti-Doping Agency (WADA) prohibited list, meaning competitive athletes cannot use it.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a BPC-157 discussion.

Comparison and Related Research

BPC-157 is most often compared with other tissue-repair and recovery-focused peptides. The comparisons below break down how each compound differs in mechanism, evidence base, and research focus.

Head-to-head comparisons

Full research comparisons covering BPC-157 and another peptide side by side.

BPC-157 vs TB-500

Side-by-side research comparison of BPC-157 and TB-500 for tissue repair. Mechanisms, evidence, and limitations from published research.

View full comparison

BPC-157 vs TB-500

Three-way comparison of BPC-157, TB-500, and GHK-Cu for tissue repair and regeneration research. Mechanisms, evidence levels, study types, and key limitations analyzed.

View full comparison

BPC-157 vs GLP-1 Based Medications

How FDA-approved GLP-1 medications differ from research-stage peptides in evidence quality, regulatory status, and use context. A neutral, evidence-based explainer from the Peptide Science Institute.

View full comparison

BPC-157 vs Semaglutide

Research comparison of BPC-157 and Semaglutide, a tissue repair peptide versus an FDA-approved GLP-1 receptor agonist. Mechanisms, evidence levels, use cases, and limitations analyzed.

View full comparison

BPC-157 vs Thymosin Alpha-1

Research comparison of Thymosin Alpha-1 and BPC-157, an immune-modulating thymic peptide versus a tissue repair gastric peptide. Mechanisms, evidence levels, and use cases analyzed.

View full comparison

BPC-157 vs GHK-Cu

BPC-157 targets deep tissue repair. GHK-Cu targets skin and collagen. Evidence-graded comparison of mechanisms, study data, and which peptide fits which goal.

View full comparison

BPC-157 vs KPV

BPC-157 has extensive gut research. KPV has anti-inflammatory mechanisms but less direct gut evidence. Evidence-graded comparison for gut healing peptides.

View full comparison

BPC-157 vs CJC-1295

BPC-157 repairs tissue. CJC-1295 elevates growth hormone. Evidence-graded comparison of two peptides that serve fundamentally different purposes.

View full comparison

BPC-157 vs Ipamorelin

BPC-157 repairs specific tissue damage. Ipamorelin optimizes GH systemically. Evidence-graded comparison of two peptides from different categories.

View full comparison

BPC-157 vs Cerebrolysin

BPC-157 for tissue repair. Cerebrolysin for neurological recovery. Both Human Trials but targeting different organ systems. Evidence-graded comparison.

View full comparison

BPC-157 vs Pentosan Polysulfate

Pentosan has specific joint and bladder research. BPC-157 has broad tissue repair evidence. Neither FDA-approved for osteoarthritis. Evidence compared.

View full comparison

Research blends

Some researchers and clinicians study BPC-157 in combination with other peptides. These blends are covered in dedicated pages with their own evidence assessments.

BPC-157 and TB-500 Blend (Wolverine Stack)

BPC-157 targets localized healing through blood vessel formation. TB-500 acts systemically through cell migration. The two mechanisms do not overlap, which is why researchers study them together.

View blend page

BPC-157, TB-500, and GHK-Cu Blend (Glow Stack)

Adds GHK-Cu, a copper peptide studied for collagen production, skin remodeling, and hair follicle support.

View blend page

BPC-157, TB-500, GHK-Cu, and KPV Blend (KLOW Stack)

Adds KPV, a peptide studied for reducing inflammatory signaling.

View blend page

Related compounds

TB-500 GHK-Cu Thymosin Beta-4 CJC-1295 Ipamorelin KPV Thymosin Alpha-1 LL-37

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Review of how BPC-157 activates backup blood-flow pathways to help heal damaged tissue in animal studies.Sikiric P et al., 2023 in Curr Med Chem. View on PubMed
2.Found that BPC-157 reduced damage to the liver, kidneys, and lungs in rats after blood flow was cut off and restored to the legs.Demirtas H et al., 2025 in Medicina (Kaunas). View on PubMed
3.Showed faster muscle-to-bone reattachment in rats after surgical detachment of the thigh muscle.Matek D et al., 2025 in Pharmaceutics. View on PubMed
4.Review of how BPC-157 promotes new blood vessel growth and interacts with the body's nitric oxide signaling system in animal models.Sikiric P et al., 2025 in Pharmaceuticals (Basel). View on PubMed
5.Found that BPC-157 protected the liver from radiation damage in rats by activating a specific repair gene (KLF4).Huang BS et al., 2022 in Life Sci. View on PubMed
6.Demonstrated that BPC-157 helped heal an abnormal connection between the intestine and colon in rats, protecting the gut lining.Vukusic D et al., 2024 in J Physiol Pharmacol. View on PubMed
7.Showed that BPC-157 helped heal a perforated stomach in rats by regulating the body's nitric oxide system, which controls blood flow and inflammation.Sikiric P et al., 2022 in Curr Pharm Des. View on PubMed
8.Independent review of BPC-157's gut-protective properties, confirming the pattern of protection against multiple types of gut damage in animal models.Whitehouse M, 2025 in Inflammopharmacology. View on PubMed
9.Primarily a rat study that also included observations of acute pancreatitis patients. The human component was observational with no comparison group.Petrovic I et al., 2011 in J Physiol Pharmacol. View on PubMed
10.Small safety study giving BPC-157 intravenously to a small number of people. Found no serious side effects, but the study had no comparison group and very few participants.Lee E, Burgess K, 2025 in Altern Ther Health Med. View on PubMed
11.Small study testing BPC-157 in patients with bladder pain (interstitial cystitis). Reported symptom improvement, but the study had no comparison group.Lee E et al., 2024 in Altern Ther Health Med. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.